Also, DCIR blockade was recently shown to reduce the incidence of experimental inflammation-induced colon carcinoma (161) and the potential of LAIR1 blockade in cancer immunotherapy is rapidly emerging (179, 182). The gene discussed is CLEC4A; the disease is cancer.